Showing 2061-2070 of 3038 results for "".
- FDA Clears ViGeneron's IND for Novel mRNA Gene Therapy to Treat Stargardt Disease and Other Retinal Dystrophieshttps://modernod.com/news/fda-clears-vigenerons-ind-for-novel-mrna-trans-splicing-gene-therapy-vg801-to-treat-stargardt-disease-and-other-abca4-linked-retinal-dystrophies/2482585/ViGeneron announced that the FDA has cleared the investigational new drug (IND) application for the phase 1/2 study of VG801, a gene therapy candidate to treat Stargardt disease and other retinal dystrophies associated with mutations in the&n
- Bausch + Lomb Acquires Elios Vision to Bolster Glaucoma Surgical Portfoliohttps://modernod.com/news/bausch-lomb-acquires-elios-vision-to-bolster-glaucoma-surgical-portfolio/2482575/Bausch + Lomb announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, a minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. Financial terms of the deal were not disclosed. According to B+
- Johnson & Johnson Appoints Shawn Millerick President, Vision Care, Americashttps://modernod.com/news/johnson-johnson-appoints-shawn-millerick-president-vision-care-americas/2482556/Johnson & Johnsonhas announced the appointment of Shawn Millerick as President, Vision Care, Americas, effective November 11, 2024. Mr. Millerick will be responsible for defining strategy and driving growth for Johnson & Johnson’s Vision Care portfolio in North Americ
- FDA Notifies Ocular Therapeutix that SOL-R Trial is Appropriate as a Registrational Study in Wet AMDhttps://modernod.com/news/fda-notifies-ocular-therapeutix-that-sol-r-trial-is-appropriate-as-a-registrational-study-in-wet-amd/2482388/Ocular Therapeutix announced that it has received a written response from the FDA that the phase 3 SOL-R clinical trial is appropriate for use as the company’s second adequate and well controlled study of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the
- FDA Clears AEYE Health's Autonomous AI for Portable Diabetic Retinopathy Screeninghttps://modernod.com/news/fda-clears-aeye-healths-autonomous-ai-for-portable-diabetic-retinopathy-screening/2482255/AEYE Health has received the first FDA clearance for a fully autonomous AI that diagnoses referable diabetic retinopathy from retinal images obtained by a handheld camera. AEYE Diagnostic Screening technology (AEYE-DS) is already cleared by the FDA and commercially availa
- Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase 2 Trialshttps://modernod.com/news/qlaris-bios-novel-iop-lowering-product-qls111-is-dosed-in-phase-2-trials/2482195/Qlaris Bio announced the initiation and dosing of two separate US phase 2 masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma. “The start of these phase 2 trials represents a key milestone in our goal of bringing QLS‑111
- New Study Shows Eylea HD with Extended 12- or 16-Week Dosing Demonstrated Noninferior Vision Gains to Standard of Care Eyleahttps://modernod.com/news/lancet-study-eylea-hd-with-extended-12-or-16-week-dosing-demonstrated-noninferior-vision-gains-to-standard-of-care-eylea/2482151/Regeneron announced The Lancet published 1-year results from the pivotal PULSAR and
- Telios Pharma Announces Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/telios-pharma-announces-successful-phase-2-results-for-tl-925-a-novel-treatment-for-dry-eye-disease/2482150/Telios Pharma announced topline results from its phase 2 study assessing TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor for individuals with moderate to severe dry eye disease (DED). This proof-of-concept, multicenter, randomized, double-masked study evaluated the
- CorNeat EverPatch Synthetic Tissue Substitute Now Available in the UShttps://modernod.com/news/corneat-everpatch-synthetic-tissue-substitute-now-available-in-the-us/2482138/CorNeat Vision announced the commerical launch of the CorNeat EverPatch, a synthetic tissue-integrating matrix for ocular surface surgeries. The EverPatch, which received FDA 510(k) clearance in June 2023, offers a combination of features that provide an advantage over ex
- Johnson & Johnson Buys Gene Therapy Eye Portfolio from MeiraGTxhttps://modernod.com/news/johnson-johnson-buys-gene-therapy-for-x-linked-retinitis-pigmentosa-from-meiragtx/2482024/Johnson & Johnson, through its Janssen Pharmaceuticals division, has acquired the rights to investigational gene therapy botaretigene sparoparvovec (bota-vec; formerly AAV-RPGR) for patients with the inherited retinal disease X-linked retinitis pigmentosa (XLRP) from MeiraGTx.<